single5MG
BPC-157
5MG Protocol
BPC-157 5MG
Injection Freq.
Once daily
Cycle Sched.
8–12 weeks; optional extension to 16 weeks
Reconstitution
3.0 mL BAC water
Supports tissue repair in preclinical gut, tendon, muscle, and skin models
Anti-inflammatory and cytoprotective activity reported in preclinical work
Good tolerability reported in early-phase safety research
1
Reconstitution Requirements
- 3.0 mL BAC water
| Step | Week Range | Dose | Units |
|---|---|---|---|
| 1 | Weeks 1–2 | 200 mcg (0.2 mg) | 12 |
| 2 | Weeks 3–4 | 400 mcg (0.4 mg) | 24 |
| 3 | Weeks 5+ | 600 mcg (0.6 mg) | 36 |
Once daily
8–12 weeks; optional extension to 16 weeks
BPC-157 is presented as a stable gastric pentadecapeptide analog studied for broad tissue-protective effects. Mechanistically, the protocol describes it as modulating nitric oxide pathways and coordinating repair signaling through growth-factor interactions that support vascularization and extracellular-matrix rebuilding. In animal research, these pathways are associated with faster angiogenesis, improved collagen deposition, and more organized remodeling in damaged tissue. The protocol also highlights anti-inflammatory and cytoprotective characteristics, which may contribute to improved recovery dynamics in musculoskeletal and gastrointestinal models. While early human safety work is referenced, the overall explanation emphasizes that most mechanistic confidence comes from preclinical data rather than large controlled human trials. For spreadsheet purposes, the key “how it works” concept is BPC-157’s multi-pathway repair signaling—vascular support, collagen/matrix regulation, and inflammatory tone modulation.
Mild injection-site reactions (redness/itching)
Limited long-term human safety/efficacy data
- Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
- Add diluent slowly down the vial wall to minimize foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label vial with reconstitution date and concentration; protect from light
- Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
- Avoid repeated freeze–thaw cycles
- Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
- Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)